Skip to content

A retrospective study on the effect of heterozygous lipid removal in the treatment of hyperlipidemia

Retrospective study on the effect of centrifugal-membrane dual plasma exchange in the treatment of hyperlipidemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084627
Enrollment
Unknown
Registered
2024-05-21
Start date
2024-05-27
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipemia

Interventions

control group:NA

Sponsors

The First Affiliated Hospital of Army Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Outpatient or inpatient patients; ? Patients diagnosed with hyperlipidemia in our hospital (triglycerides in the lipid index were greater than the upper limit of the normal value [range (0.4-1.73) mmol/L]); (3) One or more blood lipid removal treatments were performed, which were heterozygous blood lipid removal mode or single plasma exchange removal mode; ? Age 18-80 years old; ? There were blood lipid index detection records before and after treatment: serum total cholesterol, triglyceride, high (low) density lipoprotein; (6) Record height, weight, age and registration of treatment equipment; Serum lipid removal treatment records: vital signs (BP, HR, SPO2), routine blood values (wbc, rbc, Plt, Hct, Hb), coagulation function (TP) values, whole blood volume, circulation volume, serum lipid removal dose and adverse reactions were recorded.

Exclusion criteria

Exclusion criteria: ? Treatment interruption: membrane rupture, allergic reaction and other reasons did not complete lipid removal treatment; ? Lack of patient data: only one key index was archived before and after treatment;

Design outcomes

Primary

MeasureTime frame
Blood lipid indexes before and after treatment: serum total cholesterol, triglyceride, high (low) density lipoprotein;

Secondary

MeasureTime frame
General data statistics (diagnosis, sex, age, height, weight, whole blood volume);Blood routine values (wbc, rbc, Plt, Hb, HCT), vital signs (BP, HR, SPO2), coagulation function (TP) values, circulation amount, removal of lipid and whether there were adverse reactions were recorded;

Countries

China

Contacts

Public ContactZhongmei Yi

The First Affiliated Hospital of Army Military Medical University

yizhongmei2010@163.com+86 23 6876 6670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026